The diabetes and weight loss medications Ozempic and Wegovy are now considered to be available after more than two years of ...

The two major party candidates provide ample reasons for pessimism about the future of the republic. If you're a fanatical ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

Hims & Hers Health shares are falling Thursday following an FDA update listing Novo Nordisk diabetes drug Ozempic and weight-loss drug Wegovy as available, signaling possible supply stability. Here's ...

Eli Lilly ( LLY) is planning to advertise its blockbuster weight loss drug, Zepbound, for the first time next month. Despite investor and industry recognition of the branded GLP-1 drug, "unaided ...

All doses of the two drugs are now listed as available in the U.S., per an FDA database, although the company cautioned ...

It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...

LLY had $11.4 billion in revenue for the quarter (up 20% versus Q3 figures from last year), with a net income of $970 million ...

Hims & Hers (HIMS) stock fell 14% following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no longer ...

The FDA on Wednesday updated its drug shortage database to say that all dosages and versions of Novo Nordisk's Wegovy and Ozempic are ...